Aceto Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:3em;'>ACE</div>
ACET -- USA Stock  

USD 13.18  0.34  2.51%

Auris Medical would recover faster from the latest fall as its shares price went up 4.82% to Aceto's 99.19%As many rational traders are trying to avoid healthcare space, it makes sense to review Aceto a little further and understand how it stands against Auris Medical and other similar entities. We are going to break down some of the competitive aspects of both Aceto and Auris.
Published over a month ago
View all stories for Aceto | View All Stories
Should we be acquiring Auris or Aceto?
By analyzing existing basic indicators between Aceto and Auris, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Auris with a short position in Aceto. Check out our pair correlation module for more information.

Let's begin by analyzing the assets. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Aceto has an asset utilization ratio of 126.29 percent. This implies that the company is making $1.26 for each dollar of assets. An increasing asset utilization means that Aceto is more efficient with each dollar of assets it utilizes for everyday operations.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two companies, such as Aceto or DYADIC is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.

How important is Aceto's Liquidity

Aceto financial leverage refers to using borrowed capital as a funding source to finance Aceto ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Aceto financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Aceto's total debt and its cash.

Correlation Between Aceto and DYADIC INTERNATIONAL INC

In general, stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding Aceto together with similar or unrelated positions with a negative correlation. For example, you can also add DYADIC INTERNATIONAL to your portfolio. If DYADIC INTERNATIONAL is not perfectly correlated to Aceto it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When Aceto for example, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down. Please check pair correlation details between ACET and DYAI for more information.

Breaking down Aceto Indicators

Cash and Equivalents Breakdown

Lets now take a look at Aceto cash and equivalents. In accordance with the recently published financial statements, Aceto has 42.8 M in Cash and Equivalents. This is 94.79% lower than that of the Healthcare sector and 88.1% lower than that of the Drug Manufacturers - Specialty & Generic industry. The cash and equivalents for all United States stocks is 98.42% higher than that of Aceto. As for Auris Medical we see cash and equivalents of 5.31 M, which is 98.52% lower than that of the Drug Manufacturers - Specialty & Generic

359.7 M
ACET42.8 Million10.49
Sector359.72 Million88.2
EARS5.31 Million1.3

Aceto price drop is misleading

Newest Risk Adjusted Performance is up to 0.07. Price may drop again. Aceto exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate Aceto individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about Aceto future systematic risk. Aceto is a potential penny stock. Although Aceto may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Aceto. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Whereas some other firms in the drug manufacturers - specialty & generic industry are either recovering or due for a correction, Aceto may not be performing as strong as the other in terms of long-term growth potentials. To conclude, as of the 18th of September 2020, we see that Aceto follows the market closely. The firm is overvalued with average probability of financial unrest within the next 24 months. Our current 30 days buy-or-sell advice on the firm is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Aceto. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to